MGNX MacroGenics Inc.

MacroGenics to Participate in Upcoming Investor Conferences

MacroGenics to Participate in Upcoming Investor Conferences

ROCKVILLE, MD, Feb. 06, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the following investor conferences in February 2023:

  • Guggenheim Healthcare Talks | Oncology Day (New York). MacroGenics’ President & Chief Executive Officer, Scott Koenig, M.D., Ph.D., will participate in a fireside chat on Thursday, February 9, 2023, at 2:45 pm ET.  MacroGenics’ management will also participate in one-on-one meetings.
  • SVB Securities Global Biopharma Conference (Virtual). Scott Koenig, M.D., Ph.D., will participate in a formal presentation session with a SVB Securities research analyst on Tuesday, February 14, 2023, at 3:00 pm ET.  MacroGenics’ management will also participate in one-on-one meetings.

A webcast of the above presentations may be accessed under "Events & Presentations" in the Investor Relations section of MacroGenics' website at /events.cfm.  The Company will maintain an archived replay of this webcast on its website for 30 days.   

About MacroGenics, Inc.



MacroGenics (the Company) is a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody-based technology platforms, which have applicability across broad therapeutic domains. The combination of MacroGenics' technology platforms and protein engineering expertise has allowed the Company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. For more information, please see the Company's website at MacroGenics and the MacroGenics logo are trademarks or registered trademarks of MacroGenics, Inc.

###



CONTACTS:
Jim Karrels, Senior Vice President, CFO
1-301-251-5172,
EN
06/02/2023

Underlying

MGNXMacroGenics Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on MacroGenics Inc.

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke
EUR 46.86
NEO NeoGenomics In...
MYGN Myriad Genetics... ... (+32)

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

NEO NEOGENOMICS INC.
MYGN MYRIAD GENETICS INC.
MGNX MACROGENICS INC.
IMMR IMMERSION CORP.
FISV FISERV INC.
FB FACEBOOK INC. CLASS A
BG BUNGE LIMITED
ALDX ALDEYRA THERAPEUTICS
AEIS ADVANCED ENERGY INDUSTRIES INC.
UVE UNIVERSAL INSURANCE HOLDINGS INC.
GDEN GOLDEN ENTERTAINMENT
AUP AURINIA PHARMACEUTICALS INC.
SPOK SPOK HOLDINGS
INTT INTEST CORP.
YEXT YEXT
MTW MANITOWOC COMPANY INC.
PMTS CPI CARD GROUP
AMD ADVANCED MICRO DEVICES INC.
CDMO AVID BIOSERVICES
OSPN ONESPAN
ISEE IVERIC BIO
ETNB 89BIO
ARNC ARCONIC CORPORATION
GBTC GRAYSCALE BITCOIN TRUST (BTC)
IAS INTEGRAL AD SCIENCE HOLDING CORP.
BMEA BIOMEA FUSION INC
INTA INTAPP INC
FLYW FLYWIRE CORP
MNTV MOMENTIVE GLOBAL INC
ACLX ONTO INNOVATION INC.
DTC ARCELLX INC
DEFENCE THERAPEUTICS INC
03/16/23 March 16, 2023 1 EN
 PRESS RELEASE
Free
MGNX MacroGenics In...

MacroGenics Provides Corporate Update and 2022 Financial Results

MacroGenics Provides Corporate Update and 2022 Financial Results Cash runway extended through 2025 with $250 million in non-dilutive funding over past eight months TAMARACK study design modified with objective of accelerating data readoutEncouraging lorigerlimab (PD-1 × CTLA-4 bispecific DART® molecule) monotherapy clinical data presented at ASCO-GUConference call scheduled for today at 4:30 p.m. ET ROCKVILLE, Md., March 15, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeuti...

March 15, 2023 1 EN
 PRESS RELEASE
Free
MGNX MacroGenics In...

MacroGenics Announces Sale of TZIELD™ Royalty Interest for up to $200 ...

MacroGenics Announces Sale of TZIELD™ Royalty Interest for up to $200 Million ROCKVILLE, MD, March 08, 2023 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that it has entered into an agreement to sell its royalty interest on future global net sales of TZIELD (teplizumab-mzwv) to a wholly-owned subsidiary of DRI Healthcare Trust for up to $200 million. MacroGenics retains its other economic interests related to TZIELD,...

March 8, 2023 1 EN
 PRESS RELEASE
Free
MGNX MacroGenics In...

MacroGenics Announces Date of Fourth Quarter 2022 Financial Results Co...

MacroGenics Announces Date of Fourth Quarter 2022 Financial Results Conference Call ROCKVILLE, MD, March 07, 2023 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial results for the fourth quarter of 2022 after the market closes on Wednesday, March 15, 2023.  MacroGenics will host a conference call to discuss the financial results and recent corporate progress on Wednesday, March ...

March 7, 2023 1 EN
Jonathan Moreland
  • Jonathan Moreland
Free Trial
COP CONOCOPHILLIPS
ROP Roper Technolog... ... (+54)

InsiderInsights Weekly Report: March 4, 2023

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

COP CONOCOPHILLIPS
ROP ROPER TECHNOLOGIES INC.
DPZ DOMINO'S PIZZA INC.
WTFC WINTRUST FINANCIAL CORPORATION
VYGR VOYAGER THERAPEUTICS INC.
TCBI TEXAS CAPITAL BANCSHARES INC.
RNG RINGCENTRAL INC. CLASS A
PYPL PAYPAL HOLDINGS INC
PSA PUBLIC STORAGE
PGRE PARAMOUNT GROUP INC.
NSIT INSIGHT ENTERPRISES INC.
MKL MARKEL CORPORATION
MGNX MACROGENICS INC.
MCRI MONARCH CASINO & RESORT INC.
KPTI KARYOPHARM THERAPEUTICS
IVAC INTEVAC INC.
HOO HERBALIFE NUTRITION LTD.
FPI FARMLAND PARTNERS REIT
FMNB FARMERS NATIONAL BANC CORP.
FIS FIDELITY NATIONAL INFORMATION SERVICES INC.
DVN DEVON ENERGY CORPORATION
CPT CAMDEN PROPERTY TRUST
BECN BEACON ROOFING SUPPLY INC.
ET ENERGY TRANSFER L.P.
LNC LINCOLN NATIONAL CORPORATION
RSG REPUBLIC SERVICES INC.
IROQ IF BANCORP INC
BWFG BANKWELL FINANCIAL GROUP
ISSC INNOVATIVE SOLUTIONS & SUPPORT INC.
RDFN REDFIN CORPORATION
WTBA WEST BANCORP INC.
LAZY LAZYDAYS HOLDINGS
PRPL PURPLE INNOVATION
BOTJ INC.
CBNK BANK OF THE JAMES FINANCIAL GROUP INC.
EPSN CAPITAL BANCORP
GLT EPSILON ENERGY LIMITED
WSC GLATFELTER CORPORATION
BFI WILLSCOT MOBILE MINI HOLDINGS CORP
GEG BURGERFI INTERNATIONAL INC
PFX GREAT ELM GROUP INC
LZ PHENIXFIN CORP
AFBI LEGALZOOM.COM
SPRB INC.
BLBX AFFINITY BANCSHARES
FRST INC.
STE SPRUCE BIOSCIENCES INC
BARK BLACKBOXSTOCKS INC
OMGA PRIMIS FINANCIAL CORP
DZSI NEW STERIS LTD
GER ORIGINAL BARK CO
OMEGA THERAPEUTICS INC
DASAN ZHONE SOLUTIONS INC
GOLDMAN SACHS MLP & ENER RENAISS FD
03/05/23 March 5, 2023 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch